Dimensional Fund Advisors LP Reduces Position in Integer Holdings Corporation $ITGR

Key Points

• Dimensional Fund Advisors LP reduced its stake in Integer Holdings Corporation by 9.5%, selling 161,917 shares and owning approximately 4.41% of the company by the end of the quarter.
• Integer reported $1.55 EPS for the last quarter, slightly below the consensus estimate of $1.57, but its revenue increased by 11.4% year-over-year.
• Analysts have varied ratings on Integer, with one labeling it as a Strong Buy and the consensus rating currently at Buy, with an average price target of $140.25.

Dimensional Fund Advisors LP cut its position in Integer Holdings Corporation (NYSE:ITGR - Free Report) by 9.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,538,453 shares of the medical equipment provider's stock after selling 161,917 shares during the period. Dimensional Fund Advisors LP owned approximately 4.41% of Integer worth $181,547,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Opal Wealth Advisors LLC bought a new position in Integer in the 1st quarter valued at approximately $28,000. AdvisorNet Financial Inc purchased a new stake in shares of Integer during the first quarter valued at $28,000. Bessemer Group Inc. increased its holdings in Integer by 73.1% in the 1st quarter. Bessemer Group Inc. now owns 296 shares of the medical equipment provider's stock worth $35,000 after buying an additional 125 shares in the last quarter. Sterling Capital Management LLC raised its position in Integer by 472.9% in the 4th quarter. Sterling Capital Management LLC now owns 338 shares of the medical equipment provider's stock worth $45,000 after buying an additional 279 shares during the last quarter. Finally, Headlands Technologies LLC boosted its holdings in shares of Integer by 1,234.8% during the 1st quarter. Headlands Technologies LLC now owns 1,228 shares of the medical equipment provider's stock valued at $145,000 after acquiring an additional 1,136 shares during the last quarter. Hedge funds and other institutional investors own 99.29% of the company's stock.

Insider Buying and Selling at Integer

In related news, Director Martin C. Maxwell sold 8,720 shares of the company's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $120.56, for a total value of $1,051,283.20. Following the completion of the sale, the director directly owned 22,170 shares of the company's stock, valued at $2,672,815.20. This represents a 28.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Donald J. Spence sold 14,739 shares of Integer stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $120.38, for a total transaction of $1,774,280.82. Following the transaction, the director directly owned 18,781 shares in the company, valued at approximately $2,260,856.78. The trade was a 43.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.16% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Benchmark reduced their price objective on Integer from $150.00 to $140.00 and set a "buy" rating for the company in a research report on Friday, April 25th. Raymond James Financial cut their price target on Integer from $150.00 to $143.00 and set an "outperform" rating for the company in a research note on Friday, July 25th. Truist Financial lowered their price objective on shares of Integer from $145.00 to $137.00 and set a "buy" rating on the stock in a research note on Friday, July 25th. Wells Fargo & Company dropped their price objective on shares of Integer from $152.00 to $132.00 and set an "overweight" rating on the stock in a report on Friday, July 25th. Finally, Wall Street Zen raised shares of Integer from a "sell" rating to a "hold" rating in a report on Monday, May 19th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Integer has an average rating of "Buy" and an average target price of $140.25.

Integer Trading Up 3.6%

NYSE ITGR traded up $3.8190 during trading on Friday, hitting $110.6490. The stock had a trading volume of 256,433 shares, compared to its average volume of 373,536. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of 48.74, a P/E/G ratio of 0.84 and a beta of 1.02. The stock has a 50 day simple moving average of $113.76 and a 200 day simple moving average of $119.20. Integer Holdings Corporation has a one year low of $104.93 and a one year high of $146.36. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.18 and a current ratio of 3.41.

Integer (NYSE:ITGR - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.02). The business had revenue of $476.00 million for the quarter, compared to analysts' expectations of $464.37 million. Integer had a net margin of 4.61% and a return on equity of 12.27%. Integer's revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.30 EPS. Integer has set its FY 2025 guidance at 6.250-6.510 EPS. Sell-side analysts predict that Integer Holdings Corporation will post 6.01 earnings per share for the current year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.